日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)

呼吸道合胞病毒单克隆抗体Nirsevimab免疫接种与安慰剂治疗下呼吸道感染的疗效比较：一项3期随机临床试验（MELODY）的分析

期刊:Clinical Infectious Diseases
影响因子:7.3
doi:10.1093/cid/ciae596
Arbetter, Doug; Gopalakrishnan, Vancheswaran; Aksyuk, Anastasia A; Ahani, Bahar; Chang, Yue; Dagan, Ron; Esser, Mark T; Hammitt, Laura L; Mankad, Vaishali S; Saez-Llorens, Xavier; Shen, David; Leach, Amanda; Kelly, Elizabeth J; Villafana, Tonya; Wilkins, Deidre
单克隆抗体
炎症/感染
免疫/内分泌
微生物学
发表日期：2025
文献求助 收藏

Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication

贝那利珠单抗治疗重度嗜酸性粒细胞性哮喘的生物制剂应用及关键临床亚组：真实世界 XALOC-1 项目：出版物简明摘要

期刊:Immunotherapy
影响因子:2.3
doi:10.1080/1750743X.2025.2457931
Jackson, David J; Pelaia, Girolamo; Emmanuel, Benjamin; Tran, Trung N; Cohen, David; Shih, Vivian H; Shavit, Anat; Arbetter, Douglas; Katial, Rohit; Rabe, Adrian Paul J; Garcia Gil, Esther; Pardal, Marisa; Nuevo, Javier; Watt, Michael; Boarino, Silvia; Kayaniyil, Sheena; Loureiro, Claudia Chaves; Padilla-Galo, Alicia
细胞生物学
哮喘
粒细胞
发表日期：2025
文献求助 收藏

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme

贝那利珠单抗治疗重度嗜酸性粒细胞性哮喘，按既往生物制剂使用情况和关键临床亚组进行分组：真实世界 XALOC-1 项目

期刊:European Respiratory Journal
影响因子:21
doi:10.1183/13993003.01521-2023
Jackson, David J; Pelaia, Girolamo; Emmanuel, Benjamin; Tran, Trung N; Cohen, David; Shih, Vivian H; Shavit, Anat; Arbetter, Douglas; Katial, Rohit; Rabe, Adrian Paul J; Garcia Gil, Esther; Pardal, Marisa; Nuevo, Javier; Watt, Michael; Boarino, Silvia; Kayaniyil, Sheena; Chaves Loureiro, Cláudia; Padilla-Galo, Alicia; Nair, Parameswaran
细胞生物学
哮喘
粒细胞
发表日期：2024
文献求助 收藏

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial

AZD7442（Tixagevimab/Cilgavimab）治疗轻度至中度COVID-19的安全性、有效性和药代动力学：TACKLE试验的15个月最终分析

期刊:Infectious Diseases and Therapy
影响因子:5.3
doi:10.1007/s40121-024-00931-4
Hobbs, F D Richard; Montgomery, Hugh; Padilla, Francisco; Simón-Campos, Jesus Abraham; Arbetter, Douglas; Seegobin, Seth; Kiazand, Alexandre; Streicher, Katie; Martinez-Alier, Nuria; Cohen, Taylor S; Esser, Mark T
发表日期：2024
文献求助 收藏

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial

TACKLE随机试验表明，门诊使用AZD7442（Tixagevimab/Cilgavimab）治疗6个月可预防COVID-19住院，并减缓症状进展。

期刊:Infectious Diseases and Therapy
影响因子:5.3
doi:10.1007/s40121-023-00861-7
Hobbs, F D Richard; Montgomery, Hugh; Padilla, Francisco; Simón-Campos, Jesus Abraham; Kim, Kenneth; Arbetter, Douglas; Padilla, Kelly W; Reddy, Venkatesh Pilla; Seegobin, Seth; Streicher, Katie; Templeton, Alison; Viani, Rolando M; Johnsson, Eva; Koh, Gavin C K W; Esser, Mark T
发表日期：2023
文献求助 收藏

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)

对使用 AZD7442（Tixagevimab/Cilgavimab）早期门诊治疗 COVID-19 后 SARS-CoV-2 新兴变异株的分析（TACKLE 试验）

期刊:Infectious Diseases and Therapy
影响因子:5.3
doi:10.1007/s40121-023-00882-2
Kijak, Gustavo H; Ahani, Bahar; Arbetter, Douglas; Chuecos, Fernando; Gopalakrishnan, Vancheswaran; Beloor, Jagadish; Brady, Tyler; Nguyen, Amy; Roe, Tiffany L; Schuko, Nicolette; Zhang, Tianhui; Hobbs, F D Richard; Padilla, Francisco; Kelly, Elizabeth J; Montgomery, Hugh; Streicher, Katie
SARS-CoV-2
发表日期：2023
文献求助 收藏

Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

评估肌注tixagevimab-cilgavimab治疗COVID-19早期门诊疗效和安全性（TACKLE）：一项3期随机、双盲、安慰剂对照试验

期刊:Lancet Respiratory Medicine
影响因子:32.8
doi:10.1016/S2213-2600(22)00180-1
Montgomery, Hugh; Hobbs, F D Richard; Padilla, Francisco; Arbetter, Douglas; Templeton, Alison; Seegobin, Seth; Kim, Kenneth; Campos, Jesus Abraham Simón; Arends, Rosalinda H; Brodek, Bryan H; Brooks, Dennis; Garbes, Pedro; Jimenez, Julieta; Koh, Gavin C K W; Padilla, Kelly W; Streicher, Katie; Viani, Rolando M; Alagappan, Vijay; Pangalos, Menelas N; Esser, Mark T
发表日期：2022
文献求助 收藏

Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

接受冠状动脉支架植入术的房颤患者，采用利伐沙班或剂量调整的口服维生素K拮抗剂两种治疗策略后，再次住院情况的比较

期刊:Circulation
影响因子:38.6
doi:10.1161/CIRCULATIONAHA.116.025783
Gibson, C Michael; Pinto, Duane S; Chi, Gerald; Arbetter, Douglas; Yee, Megan; Mehran, Roxana; Bode, Christoph; Halperin, Jonathan; Verheugt, Freek W A; Wildgoose, Peter; Burton, Paul; van Eickels, Martin; Korjian, Serge; Daaboul, Yazan; Jain, Purva; Lip, Gregory Y H; Cohen, Marc; Peterson, Eric D; Fox, Keith A A
发表日期：2017
文献求助 收藏

Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy

急性重症内科患者接受延长疗程贝曲沙班与标准剂量依诺肝素治疗后发生致命或不可逆事件的比较：一项APEX试验子研究

期刊:Journal of the American Heart Association
影响因子:5.3
doi:10.1161/JAHA.117.006015
Gibson, C Michael; Korjian, Serge; Chi, Gerald; Daaboul, Yazan; Jain, Purva; Arbetter, Douglas; Goldhaber, Samuel Z; Hull, Russel; Hernandez, Adrian F; Lopes, Renato D; Gold, Alex; Cohen, Alexander T; Harrington, Robert A
发表日期：2017
文献求助 收藏